Literature DB >> 8953853

The genotypes of hepatitis C virus in patients with chronic hepatitis C virus infection in southern Taiwan.

M L Yu1, W L Chuang, S N Lu, S C Chen, J H Wang, Z Y Lin, M Y Hsieh, L Y Wang, W Y Chang.   

Abstract

To investigate the genotype distribution of hepatitis C virus (HCV) in southern Taiwan, the sera from 56 patients with chronic HCV infection were studied. Twenty-nine patients were men and 27 were women. Age ranged from 22 to 65 years (mean, 47.3 +/- 11.4). Eighteen of them had chronic persistent hepatitis, 27 had chronic active hepatitis, and 11 had liver cirrhosis. HCV RNA was detected by reverse transcription-nested polymerase chain reaction using primers derived from the 5'-noncoding region. The genotypes of HCV were determined by amplification of the core region with the type-specific primers as described by Okamoto et al.. All sera were positive for HCV RNA. The prevalence rates of genotypes were as follows: 1b/II, 44.6%(25/56); 2a/III, 41.1%(23/56); 2b/IV, 3.6%(2/56); mixed 1b/I + 2a/III, 5.4%(3/56): mixed 1b/II + 2b/IV, 1.8%(1/56) and type unclassified 3.6%(2/56). The distribution of genotypes was not related to the patients' age, sex, and histological changes. Nevertheless, patients having past history of blood transfusion had a significantly higher rate of HCV type 2a/III infection (72.2% versus 34.2%, p < .05, chi-square test). We concluded that both of the HCV genotypes 1 b/II and 2a/III are predominant types in southern Taiwan and regional HCV genotype distribution may differ even within this island. Selective transmission of specific genotypes may pass along different infectious routes.

Entities:  

Mesh:

Year:  1996        PMID: 8953853

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  6 in total

1.  Clinical application of the Quantiplex HCV RNA 2.0 and Amplicor HCV Monitor assays for quantifying serum hepatitis C virus RNA.

Authors:  M L Yu; W L Chuang; S C Chen; Z Y Lin; M Y Hsieh; L Y Wang; W Y Chang
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

2.  Prevalence and clinical significance of SEN virus infection among volunteer blood donors in southern Taiwan.

Authors:  Chia-Yen Dai; Ming-Lung Yu; Zu-Yau Lin; Shinn-Cherng Chen; Ming-Yuh Hsieh; Liang-Yen Wang; Jung-Fa Tsai; Wan-Long Chuang; Wen-Yu Chan
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

3.  Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy.

Authors:  Hsien-Hong Lin; Shih-Jer Hsu; Sheng-Nan Lu; Wan-Long Chuang; Chao-Wei Hsu; Rong-Nan Chien; Sien-Sing Yang; Wei-Wen Su; Jaw-Ching Wu; Tzong-Hsi Lee; Cheng-Yuan Peng; Kuan-Chiao Tseng; Albert Qin; Yi-Wen Huang; Pei-Jer Chen
Journal:  JGH Open       Date:  2021-07-10

4.  The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan.

Authors:  Ying-Chou Huang; Chung-Feng Huang; Shu-Fen Liu; Hung-Yin Liu; Ming-Lun Yeh; Ching-I Huang; Meng-Hsuan Hsieh; Chia-Yen Dai; Shinn-Chern Chen; Ming-Lung Yu; Wan-Long Chuang; Jee-Fu Huang
Journal:  PLoS One       Date:  2021-01-29       Impact factor: 3.240

5.  Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan.

Authors:  Ming-Ying Lu; Chun-Ting Chen; Yu-Lueng Shih; Pei-Chien Tsai; Meng-Hsuan Hsieh; Chung-Feng Huang; Ming-Lun Yeh; Ching-I Huang; Shu-Chi Wang; Yi-Shan Tsai; Yu-Min Ko; Ching-Chih Lin; Kuan-Yu Chen; Yu-Ju Wei; Po-Yao Hsu; Cheng-Ting Hsu; Tyng-Yuan Jang; Ta-Wei Liu; Po-Cheng Liang; Ming-Yen Hsieh; Zu-Yau Lin; Shinn-Cherng Chen; Jee-Fu Huang; Chia-Yen Dai; Wan-Long Chuang; Ming-Lung Yu; Wen-Yu Chang
Journal:  Sci Rep       Date:  2021-04-20       Impact factor: 4.379

6.  Hepatitis C virus infection among injection drug users with and without human immunodeficiency virus co-infection.

Authors:  Meng-Hsuan Hsieh; Jih-Jin Tsai; Ming-Yen Hsieh; Chung-Feng Huang; Ming-Lun Yeh; Jeng-Fu Yang; Ko Chang; Wei-Ru Lin; Chun-Yu Lin; Tun-Chieh Chen; Jee-Fu Huang; Chia-Yen Dai; Ming-Lung Yu; Wan-Long Chuang
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.